Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 160.00
Bid: 155.00
Ask: 165.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.452%)
Open: 160.00
High: 160.00
Low: 160.00
Prev. Close: 160.00
TIDE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
17th Apr 202410:05 amRNSBoard Changes
17th Apr 20247:00 amRNSPreliminary Results to 31 December 2023
23rd Jan 20247:00 amRNSTrading Update
28th Nov 20237:00 amRNSTrading Update
31st Oct 202311:45 amRNSResult of GM, Share Consolidation & TVR
10th Oct 20237:00 amRNSContract increases and extensions
6th Oct 20237:00 amRNSFurther re: Proposed Share Consolidation
5th Oct 20237:00 amRNSProposed Share Consolidation
26th Sep 20237:00 amRNSDirector dealing
25th Sep 20237:00 amRNSInterim Results
20th Sep 20237:00 amRNSContract Win
14th Sep 20237:00 amRNSStrengthened Operating Board
20th Jun 20234:20 pmRNSResult of AGM and Statement
31st May 20237:00 amRNSBoard changes
31st May 20237:00 amRNSPosting of Annual Report and Notice of AGM
10th May 20232:10 pmRNSDirectorate Change
4th May 20237:00 amRNSContract Win and Renewals
12th Apr 20237:00 amRNSPreliminary Results
5th Apr 20237:00 amRNSContract Win
1st Mar 20237:00 amRNSNotice of Results and Investor Presentation
7th Feb 20232:00 pmRNSHolding(s) in Company
6th Feb 20233:55 pmRNSHolding(s) in Company
1st Feb 20237:00 amRNSContract Win
18th Jan 20237:00 amRNSTrading Update
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.